Title: Pharmacokinetics and bioavailability of long acting moxifloxacin in goats
Authors: Anjana Kumari, RK Nirala, Archana Kumari and SK Mody
Source: Ruminant Science (2017)-6(2):283-285.
Cite this reference as: Kumari Anjana, Nirala RK, Kumari Archana and Mody SK (2017). Pharmacokinetics and bioavailability of long acting moxifloxacin in goats. Ruminant Science 6(2):283-285.
Moxifloxacin is a new enantiomerically pure, fourth generation fluoroquinolone that has potent antimicrobial activity against both Gram-negative and Gram-positive bacteria, anaerobes and atypical organisms. Present study was planned to investigate the pharmacokinetics of long acting moxifloxacin given by Intravenous (IV) and Intramuscular (IM) routes at the dose rate of 7.5 mg.kg-1 in six male Mehsana goats. Long Acting (LA) Moxifloxacin was injected intramuscularly and intravenously after that periodically blood samples were collected from jugular vein at different time interval up to 96 h post administration of drug. LA Moxifloxacin concentrations were determined by HPLC system with florescence detector. After IV administration the values of different pharmacokinetic parameters viz; , t1/2, AUC, AUMC, ClB and MRT were 0.08 h-1, 9.43 h, 22.92 g.h.ml-1, 181.95 g.h2.ml-1, 0.33 L.h-1.kg-1 and 7.93 h, respectively. Following IM administration the values of different pharmacokinetic parameters like; t1/2, AUC, ClB and MRT were 15.19 h. 24.12 g.h-1ml, 0.31 L-1h-1kg and 15.62 h. The bioavailability was 107.97 percent. No adverse effects have been shown by the animals during experimental period. The calculated priming and maintenance doses of LA moxifloxacin are 8.6 and 7.4 mg.kg-1 (repeated at 48 h of interval), respectively to be given IM.
Abd El-Aty AM, Goudah A, Shah SS, Shin HC, Shimoda M and Shim JH (2007). Pharmacokinetic variables of moxifloxacin in healthy male camels following intravenous and intramuscular administration. Journal of Veterinary Pharmacology and Therapeutics 30:586-591.
Baggot JD (1977). Principles of drug disposition in domestic animals. The Basis of Veterinary Clinical Pharmacology. 1st Edn, WB Saunders Co, Philadelphia, USA. pp 144-189.
Brown SA (1996). Fluroquinolones in animal health. Journal of Veterinary Pharmacology and Therapeutics 19(1):14.
Carceles CM, Serrano JM, Marin P, Escudero E and Fernandez-Varon E (2006). Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. Journal of Veterinary Medicine Series-A 53:300-304.
Carceles CM, Villamayor L, Escudero E, Marin P and Fernandez-Varon E (2007). Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. Veterinary Journal 173:452-455.
Carceles CM, Escudero E, Fernandez-Varon E and Marin P (2009). Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. Veterinary Journal 180:343-47.
Dalhoff A, Petersen U and Endermann R (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
Fernandez-Varon E, Bovaira MJ, Espuny A, Escudero E, Vancraeynest D and Carceles CM (2005). Pharmacokinetic-pharmacodynamic integration of Moxifloxacin in rabbits after intravenous, intramuscular and oral administration. Journal of Veterinary Pharmacology and Therapeutics 28:343-348.
Fernandez-Varon E, Villamayor L, Escudero E, Espuny A and Carceles CM (2006). Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. Veterinary Journal 172:302-307.
Gibaldi M and Perrier D (1982). Pharmacokinetics. 2nd Edn, Marcel Dekker Inc, New York.
Gardner SY, Davis JL, Jones SL, Lafevers DH, Hoskins MS, Mcarver EM and Papich MG (2004). Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing. Journal of Veterinary Pharmacology and Therapeutics 27:57-60.
Goudah A (2008). Disposition kinetics of Moxifloxacin in lactating ewes. Veterinary Journal 178:282-287.
Goudah A and Hasabelnaby S (2010). Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. Chemotherapy 56:26-31.
Petersen U, Dalhoff A and Endermann R (1996). Synthesis and in vitro activity of BAY 12-8039, a new 8-methoxy-quinolone. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC p 100.
Pathania R and Sharma SK (2010). Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. Research in Veterinary Science 89:108-112.
Rathod N, Kukade S, Lonare MK and Hajare SW (2014). Pharmacokinetics of moxifloxacin following intramuscular administration in berari goat a saline tract breed of vidarbha region.Ruminant Science 3(1):45-49.
Rathod NR, Kukade SV, Lonare MK and Hajare SW (2015). Influence of meloxicam on pharmacokinetic alterations of moxifloxacin in male goats. Ruminant Science 4(1):103-108.
Rouse MS, Piper KE, Patel R, Wilson WR and Steckelberg JM (1996). In vitro and in vivo activity of BAY 12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. abstr. B45 p 29.
Stass H, Dalhoff A, Kubitza D and Schuhly U (1998). Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-Methoxy quinolone, administered to healthy subjects. Antimicrobial Agents and Chemotherapy 42:2060-65.
Siefert HM, Domdey-Bette A, Henninger F, Hucke F, Kohlsdorfer C, Steinke W and Stass HH (1999). Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparisonhumans and other mammalian species. Journal of Antimicrobial Chemotherapy 43:69-76.